$1.94
Taysha Gene Therapies is a biotechnology business based in the US. Taysha Gene Therapies shares (TSHA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.02 – an increase of 1.51% over the previous week. Taysha Gene Therapies employs 52 staff and has a trailing 12-month revenue of around $12.9 million.
Our top picks for where to buy Taysha Gene Therapies Inc stock
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Taysha Gene Therapies stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – TSHA. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Taysha Gene Therapies stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Taysha Gene Therapies stock price (NASDAQ: TSHA)
Use our graph to track the performance of TSHA stocks over time.Taysha Gene Therapies shares at a glance
Latest market close | $2.02 |
---|---|
52-week range | $1.27 - $4.32 |
50-day moving average | $2.12 |
200-day moving average | $2.38 |
Wall St. target price | $6.41 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-0.49 |
Is it a good time to buy Taysha Gene Therapies stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Taysha Gene Therapies price performance over time
Historical closes compared with the close of $2.06 from 2024-10-18
1 week (2024-10-15) | 5.64% |
---|---|
1 month (2024-09-20) | -4.19% |
3 months (2024-07-22) | -5.50% |
6 months (2024-04-22) | -16.26% |
1 year (2023-10-20) | -3.29% |
---|---|
2 years (2022-10-18) | N/A |
3 years (2021-10-22) | 15.75 |
5 years (2019-10-18) | N/A |
Taysha Gene Therapies financials
Revenue TTM | $12.9 million |
---|---|
Gross profit TTM | $2.5 million |
Return on assets TTM | -34.17% |
Return on equity TTM | -318.69% |
Profit margin | 0% |
Book value | $0.54 |
Market Capitalization | $414 million |
TTM: trailing 12 months
Taysha Gene Therapies share dividends
We're not expecting Taysha Gene Therapies to pay a dividend over the next 12 months.
You may also wish to consider:
Taysha Gene Therapies share price volatility
Over the last 12 months, Taysha Gene Therapies's shares have ranged in value from as little as $1.27 up to $4.32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Taysha Gene Therapies's is 0.378. This would suggest that Taysha Gene Therapies's shares are less volatile than average (for this exchange).
To put Taysha Gene Therapies's beta into context you can compare it against those of similar companies.
- Uniqure (QURE.US): 0.944
- Voyager Therapeutics (VYGR.US): 0.908
- Inovio Pharmaceuticals (INO.US): 0.823
Taysha Gene Therapies overview
Taysha Gene Therapies, Inc. , a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Frequently asked questions
What percentage of Taysha Gene Therapies is owned by insiders or institutions?Currently 17.538% of Taysha Gene Therapies shares are held by insiders and 78.127% by institutions. How many people work for Taysha Gene Therapies?
Latest data suggests 52 work at Taysha Gene Therapies. When does the fiscal year end for Taysha Gene Therapies?
Taysha Gene Therapies's fiscal year ends in December. Where is Taysha Gene Therapies based?
Taysha Gene Therapies's address is: 3000 Pegasus Park Drive, Dallas, TX, United States, 75247 What is Taysha Gene Therapies's ISIN number?
Taysha Gene Therapies's international securities identification number is: US8776191061
More guides on Finder
-
Fundamental Analysis
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
-
Best broker cash sweep rates of 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
Titan Review 2024: Wealth Management With a No-Advisory-Fee Robo-Advisor
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
-
Public.com Review 2024: No-Fee Options, With Rebates
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
-
SoFi Invest® review 2024: Simple investing, free CFP access
SoFi Invest is a commission-free platform with both active and automated investment accounts.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
-
How to trade options
Read our beginner’s guide to trading options in the US.
Ask a question